MA (Cantab), MSc, PhD, Fellow of the Chartered Institute of Patent Attorneys, European Patent Attorney.
Michael read natural sciences (biochemistry) at Cambridge University before obtaining a PhD in biochemistry at the same university, where Merck Sharp & Dohme sponsored his research. His research involved using metabolic profiling techniques to study a childhood neurodegenerative disease. During his PhD, he authored several papers in the field of functional genomics.
Michael joined Potter Clarkson in 2006 and qualified as a Chartered Patent Attorney and European Patent Attorney in 2010. During his qualification, Michael was awarded the Peter FitzGibbon Memorial Award for obtaining the highest mark in one of his UK exams.
Michael handles a wide range of biotechnological subject matter and has particular expertise in the drafting and prosecution of patent applications concerning immunotherapy, protein stability, gene therapy, metabolic profiling, drug delivery, and assay technologies. In addition to acting before the European Patent Office, he has also managed the prosecution of several global patent portfolios, including applications in Australia, Canada, China, India, Japan and the US.
Over recent years, Michael has developed experience in the niche area of Supplementary Protection Certificates (SPCs, a form of IP that can provide an additional monopoly period beyond patent expiry for some medicinal and plant protection products). As well as authoring various articles on the topic, Michael has been involved in coordinating the prosecution of high profile SPC portfolios throughout Europe, including a case that was referred to the Court of Justice of the European Union.